Neuropsychiatric disorders are the single largest cause of disability in the world, with ~1B people suffering worldwide, and costing over $1.5T annually in the US alone. Despite the size of the problem, this field of medicine remains uniquely reliant on subjective clinician judgement for diagnosis, leading to trial and error patient care and the highest rates of drug trial failure. Unfortunately, pharma and clinics have been slow to adopt AI and digital markers of conditions because the ROI is unproven and they add burden to clinical workflow. By integrating digital markers in our assessment modules designed to decrease the burden on clinicians without replacing them, we can offer the advantages of precision medicine AI modeling while reducing clinical trial costs and empowering non-mental health specialists, such as oncologists, to track their patients mental health needs.

• Won the 2025 American Psychiatric Association's Psychiatric Innovation Labs competition and successfully graduated from the prestigious Endless Frontiers Labs accelerator in digital health (cohort of 100 selected from 1500!)
• Currently conducting a validation trial of our platform comparing its performance in administering a gold-standard, diagnostic clinical interview assessment for depression.
• Published or under review FOUR studies in peer-reviewed top journals.
• Launched Version 2.0 of our AI platform with enhanced stability, visual fidelity, and low latency.
• Submitted EIGHT grant and research proposals across industry, foundations, and federal agencies, and included as key analytics platform subcontractors in two additional large projects with our pharmaceutical partners.
• Secured an engagement as the precision analytics platform for a groundbreaking first-in-human trial of a promising DMT/harmine ayahuasca derivative.
• FOUR prestigious Consortia formed: 1) a psycho-oncology consortium featuring renowned institutions such as Memorial Sloan Kettering and Mayo Clinic to assess/address mental health challenges faced by cancer patients; 2) a space medicine consortium; 3) a digital marker consortium with non-profits, such as the Digital Medicine Society (DiMe) and the Brainclinics Foundation; 4) a substance use disorder consortium with aligned pharma (e.g. Reconnect Labs) and mental health clinic (e.g. Synaeda Psycho Medisch Centrum) companies.